Evaluation of the Negative Predictive Value of Methicillin-Resistant Staphylococcus aureus Nasal Swab Screening in the Medical Intensive Care Units and Its Effect on Antibiotic Duration - PubMed (original) (raw)

Evaluation of the Negative Predictive Value of Methicillin-Resistant Staphylococcus aureus Nasal Swab Screening in the Medical Intensive Care Units and Its Effect on Antibiotic Duration

Chih-Hsun Tai et al. Infect Drug Resist. 2022.

Abstract

Background: In addition to active surveillance of methicillin-resistant Staphylococcus aureus (MRSA) carrier, MRSA nasal screening can be valuable for antibiotic de-escalation. This study aimed to assess the correlations between the MRSA nasal swab and subsequent culture results in patients admitted to medical intensive care units (MICU). The impact of MRSA nasal swab on the antibiotic duration was also evaluated.

Materials and methods: This retrospective study enrolled patients who received glycopeptides in the MICU of a medical center in 2019. Patients treated with glycopeptides for over 2 days before MICU admission were excluded. The associated data were collected through the electronic medical record system. The negative predictive value (NPV) of MRSA nasal swabs for MRSA infection was calculated, and their influence on empirical glycopeptide treatment duration was analyzed.

Results: Of the 338 patients who met the inclusion criteria, 277 underwent MRSA nasal screening. The NPV of MRSA-negative nasal swab for subsequent MRSA infection was 98.4%. The glycopeptide treatment duration of the patients with and without nasal screening was not significantly different (4.2 ± 2.8 vs 4.4 ± 3.0 days, p = 0.577). Of the 120 patients with MRSA-negative nasal swab and no subsequent MRSA infection, 75 continued empirical glycopeptides therapy. The additional treatment time was 3 days (interquartile range: 2-6 days).

Conclusion: The MRSA nasal swabs have high NPV for MRSA infection in critically ill patients. However, it has no impact on the empirical glycopeptide treatment duration. The value of MRSA nasal swabs should be advocated to optimize antibiotic therapy.

Keywords: MRSA nasal swab; antibiotic stewardship; critical care; glycopeptides.

© 2022 Tai et al.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1

Figure 1

Flow chart.

Similar articles

Cited by

References

    1. Que YA, Moreillon P. Staphylococcus aureus (Including Staphylococcal Toxic Shock Syndrome). In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th ed. Philadelphia, PA: Elsevier, Inc.; 2020:2393–2431.
    1. Rupp ME, Fey PD. Staphylococcus epidermidis and other coagulase-negative Staphylococci. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th ed. Philadelphia, PA: Elsevier, Inc.; 2020:2432–2443.
    1. Mirzaei B, Moosavi SF, Babaei R, Siadat SD, Vaziri F, Shahrooei M. Purification and evaluation of Polysaccharide Intercellular Adhesion (PIA) antigen from Staphylococcus epidermidis. Curr Microbiol. 2016;73(5):611–617. doi:10.1007/s00284-016-1098-5 - DOI - PubMed
    1. Mirzaei B, Mousavi SF, Babaei R, et al. Synthesis of conjugated PIA-rSesC and immunological evaluation against biofilm-forming Staphylococcus epidermidis. J Med Microbiol. 2019;68(5):791–802. doi:10.1099/jmm.0.000910 - DOI - PubMed
    1. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3 - DOI - PubMed

LinkOut - more resources